Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: A cross-sectional, observational study

Clinical Drug Investigation

Volumn 31, Issue 11, 2011, Pages 759-767

  Guaraldi, Giovanni ^a   Zona, Stefano ^a   Orlando, Gabriella ^a   Carli, Federica ^a   Stentarelli, Chiara ^a   Luzi, Kety ^a   Garlassi, Elisa ^a   Menozzi, Marianna ^a   Bagni, Pietro ^a   Adorni, Fulvio ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b CNR   (Italy)

Author keywords

Acquired immunodeficiency syndrome; Antiretrovirals; Emtricitabinetenofovir disoproxil fumarate; Lamivudineabacavir; lamivudinezidovudine; Lipodystrophy; Nevirapine; Non nucleoside reverse transcriptase inhibitors nscriptase inhibitors

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE PLUS ZIDOVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INSULIN RESISTANCE; ITALY; LEG; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; OBSERVATIONAL STUDY; OUTPATIENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROLOGY; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; BODY FAT DISTRIBUTION; CROSS-SECTIONAL STUDIES; DRUG COMBINATIONS; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INSULIN RESISTANCE; ITALY; LIPODYSTROPHY; MALE; MIDDLE AGED; NEVIRAPINE; OUTPATIENTS; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; UNIVERSITIES;

EID: 80053534316     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/bf03256916     Document Type: Article

References (29)

1. Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005; 19: 917-25 (Pubitemid 40834934)
2. Fisac C, Virgili N, Ferrer E, et al. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study. J Clin Endocrinol Metab 2003; 88: 5186-92 (Pubitemid 37452715)
3. van Vonderen MG, van Agtmael MA, Hassink EA, et al. Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. PLoS One 2009; 4: e5647
4. DHSS. Panel on Antiretroviral Guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2008 Nov 3: 1-139
5. EACS. European AIDS Clinical Society (EACS) guidelines 2008. Guidelines for the clinical management and treatment of HIV infected adults in Europe. Version 4: Paris, October 2008
6. Bonjoch A, Paredes R, Domingo P, et al. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1- infected patients. AIDS Res Hum Retroviruses 2006; 22: 321-9
7. Milinkovic A, Martinez E. Nevirapine in the treatment of HIV. Expert Rev Anti Infect Ther 2004; 2: 367-73 (Pubitemid 38745097)
8. Reliquet V, Allavena C, Francois-Brunet C, et al. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study. HIV Med 2006; 7: 431-6 (Pubitemid 44269809)
9. Ribera E, Rodriguez-Pardo D, Rubio M, et al. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIVinfected patients. Antivir Ther 2005; 10: 605-14 (Pubitemid 41224952)
10. Hammer SM, Eron Jr JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA Panel. JAMA 2008; 300: 555-70
11. Bergersen BM. Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy. Drugs 2006; 66: 1971-87 (Pubitemid 44771934)
12. Clotet B, van der Valk M, Negredo E, et al. Impact of nevirapine on lipid metabolism. J Acquir Immune Defic Syndr 2003; 34 Suppl. 1: S79-84 (Pubitemid 37158637)
13. Gazzard BG. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Medicine 2008; 9: 563-608
14. Barreiro P, Soriano V, Blanco F, et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000; 14: 807-12 (Pubitemid 30303457)
15. Guaraldi G, Orlando G, SquillaceN, et al. Multidisciplinary approach to the treatment of metabolic and morphologic alterations of HIV-related lipodystrophy. HIV Clin Trials 2006; 7: 97-106 (Pubitemid 44309000)
16. Schmidt C, Fagerberg B, Wikstrand J, et al. ApoB/apoA-I ratio is related to femoral artery plaques and is predictive for future cardiovascular events in healthy men. Atherosclerosis 2006; 189: 178-85 (Pubitemid 44441279)
17. Lee S, Choi S, Kim HJ, et al. Cutoff values of surrogate measures of insulin resistance for metabolic syndrome in Korean non-diabetic adults. J Korean Med Sci 2006; 21: 695-700 (Pubitemid 44199326)
18. Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coronary heart disease: guidance from Framingham. Astatement for healthcare professionals fromtheAHATask Force on Risk Reduction. Circulation 1998; 97: 1876-87
19. Grundy SH, DAgostino RB, Mosca L, et al. Summary of National Heart, Lung, and Blood Institute workshop on cardiovascular risk assessment. National Heart, Lung, and Blood Institute, Bethesda, MD, 2003
20. Barbaro G, Iacobellis G. Metabolic syndrome associated with HIV and highly active antiretroviral therapy. Curr Diab Rep 2009; 9: 37-42
21. Guaraldi G, Stentarelli C, Zona S, et al. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis 2010; 208: 222-7
22. Petit JM, Duong M, Masson D, et al. Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors. Eur J Clin Invest 2004; 34: 569-75 (Pubitemid 39120227)
23. Calza L, Manfredi R, Colangeli V, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipidlowering therapy for the management of dyslipidaemia. AIDS 2005; 19: 1051-8 (Pubitemid 40961145)
24. Negredo E, Ribalta J, Paredes R, et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002; 16: 1383-9 (Pubitemid 34722070)
25. van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine- containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15: 2407-14 (Pubitemid 34014609)
26. Young J, Weber R, Rickenbach M, et al. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTIbased therapy in the Swiss HIV cohort study. Antivir Ther 2005; 10: 585-91 (Pubitemid 41224950)
27. Manfredi R, Calza L, Chiodo F. An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine. J Acquir Immune Defic Syndr 2005; 38: 236-8 (Pubitemid 40189333)
28. van der Valk M, Reiss P. Lipid profiles associated with antiretroviral drug choices. Curr Opin Infect Dis 2003; 16: 19-23 (Pubitemid 36205251)
29. Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13: 805-10 (Pubitemid 29224582)